Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” (Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))

THE AMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGY COUNCIL ON CARDIOVASCULAR AND STROKE NURSING HEART FAILURE SOCIETY OF AMERICA

Research output: Contribution to journalComment/debate

Abstract

In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…”

Original languageEnglish (US)
Number of pages1
JournalJournal of Cardiac Failure
Volume25
Issue number10
DOIs
StatePublished - Oct 2019

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” (Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))'. Together they form a unique fingerprint.

  • Cite this